截至2025年7月22日收盘，三生国健股价报54.44元，较前一交易日下跌4.89%，成交额4.91亿元。
三生国健是一家专注于生物医药研发的企业，主要涉及生物制品、重组蛋白及单抗药物等领域。公司总部位于上海，是国内创新药研发的重要参与者之一。
消息面上，三生国健近期与跨国药企辉瑞达成一项重磅授权交易，涉及PD-1/VEGF双抗药物SSGJ-707的海外权益。根据协议，三生国健及其关联公司获得的首付款达12.5亿美元，总交易金额超过60亿美元，创下国产创新药出海首付款纪录。此外，公司在银屑病治疗领域也有所布局，相关药物研发进展受到市场关注。
资金方面，7月22日主力资金净流出4840.44万元。
风险提示：股市有风险，投资需谨慎。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.